Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
At present 18 per cent of the local pharmaceutical market is under government's price control
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
Anti-malaria API facility will be operational in 15-18 months
Ibuprofen and Famotidine tablets approved by FDA
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Subscribe To Our Newsletter & Stay Updated
